Investor Tips New vaccine entrant gets approval before Novavax, while herd immunity ideas put sales in doubt. Articles You May Like How Rising AI Power Demand Is Fueling Utility ETFs Worried About an AI Bubble? Look to Surging International Stocks Brian’s Big Idea: Three Tech Stocks And A Popular Service at Zacks